Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Bone

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bone.2011.03.769PMID 21457806
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

  2011cited by this paper
• Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know.

  2011cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

  2010cited by this paper
• Lasofoxifene in postmenopausal women with osteoporosis.

  2010cited by this paper
• Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study.

  2010cited by this paper
• Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

  2010cited by this paper
• Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

  2009cited by this paper
• Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long‐Term Treatment With Alendronate: Clues to the Mechanism of Increased Bone Fragility

  2009cited by this paper
• Skeletal health: primate model of postmenopausal osteoporosis

  2009influential reference
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis

  2009cited by this paper
• Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

  2009cited by this paper
• Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.

  2009cited by this paper
• Skeletal Microdamage: Less About Biomechanics and More About Remodeling

  2008cited by this paper
• Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.

  2008cited by this paper
• Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

  2007cited by this paper
• Co‐Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized Mice

  2006cited by this paper
• Severely suppressed bone turnover: a potential complication of alendronate therapy.

  2005cited by this paper
• The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

  2005cited by this paper
• The RANKL Inhibitor Osteoprotegerin (OPG) Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared to Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy

  2005cited by this paper
• Bone Remodeling at the Iliac Crest Can Predict the Changes in Remodeling Dynamics, Microdamage Accumulation, and Mechanical Properties in the Lumbar Vertebrae of Dogs

  2005cited by this paper
• Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial

  2004cited by this paper
• Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

  2003cited by this paper
• Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate

  2003cited by this paper
• Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk

  2003cited by this paper
• Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys

  2002cited by this paper
• Reductions in Bone Mass, Structure, and Strength in Axial and Appendicular Skeletons Associated With Increased Turnover After Ovariectomy in Mature Cynomolgus Monkeys and Preventive Effects of Clodronate

  2002cited by this paper
• Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

  2001cited by this paper
• Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

  2000cited by this paper
• Influence of microdamage on fracture toughness of the human femur and tibia.

  1998cited by this paper
• The influence of bone morphology on fracture toughness of the human femur and tibia.

  1997cited by this paper
• Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study

  1996cited by this paper
• Basic biomechanical measurements of bone: a tutorial.

  1993cited by this paper
• Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

  1987cited by this paper
• Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

  1987cited by this paper

• In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation.

  2026cites this paper
• Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.

  2025cites this paper
• EVALUATION OF THE EFFICACY OF SYSTEMICALLY APPLIED DENOSUMAB IN THE REPAIR OF BONE DEFECTS

  2025cites this paper
• Role and mechanism of botanical drugs and their metabolites in osteoporosis: new strategies for clinical application

  2025cites this paper
• Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years

  2022cites this paper
• Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys

  2022cites this paper
• Novel bioactive collagen-polyurethane-pectin scaffolds for potential application in bone regenerative medicine

  2022cites this paper
• Bone Remodeling and Modeling: Therapeutic Targets for the Treatment of Osteoporosis

  2021cites this paper
• Osteosarcopenia in Very Old Age Adults After Hip Fracture: A Real-World Therapeutic Standpoint

  2021cites this paper
• Osteoinductive potential of recombinant BMP-9 in bone defects of mice treated with antiresorptive agents.

  2021cites this paper
• On the evolution and contemporary roles of bone remodeling

  2021cites this paper
• Perspectives on the non-invasive evaluation of femoral strength in the assessment of hip fracture risk

  2020cites this paper
• Pharmacological mechanisms of therapeutics

  2020cites this paper
• A case of pregnancy and lactation-associated osteoporosis and a review of the literature

  2020cites this paper
• Translational Pharmacology in The Development of RANKL Inhibitors

  2019cites this paper
• Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials

  2019cites this paper
• Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.

  2019cites this paper
• Editorial: What's New in Endocrinology?

  2019cites this paper
• Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.

  2019cites this paper
• Advances and Unmet Needs in the Therapeutics of Bone Fragility

  2018cites this paper
• Identification of mechanisms of acquired resistance to taxanes in triple negative breast cancer using patient-derived xenografts: a step closer to clinics

  2018cites this paper
• Reply

  2018cites this paper
• Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study

  2018cites this paper
• Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

  2018cites this paper
• Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study.

  2018cites this paper
• Lack of Effect of Teriparatide on Joint Erosions in Rheumatoid Arthritis Is an Expected Result: Comment on the Article by Solomon et al

  2018cites this paper
• Bone-Targeted Therapies in Cancer-Induced Bone Disease

  2018cites this paper
• Serum calcium concentration is maintained when bone resorption is suppressed by osteoprotegerin in young growing male rats.

  2018cites this paper
• Denosumab for the treatment of osteoporosis

  2017cites this paper
• Marine Natural Products: New Avenue in Treatment of Osteoporosis

  2017cites this paper
• Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

  2017cites this paper
• Quantitative Computed Tomography-Current Status and New Developments.

  2017cites this paper
• Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High‐Resolution Peripheral Quantitative Computed Tomography Study

  2017cites this paper
• How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders

  2017cites this paper
• Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women

  2017cites this paper
• Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients

  2017cites this paper
• Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease.

  2016cites this paper
• Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys

  2016cites this paper
• Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis

  2016cites this paper
• Bone turnover markers: Defining a therapeutic target.

  2016cites this paper
• Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate

  2016cites this paper
• Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice

  2016cites this paper
• Role of the RANK/RANKL pathway in breast cancer.

  2016cites this paper
• Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis

  2016cites this paper
• Monoclonal Antibodies for Musculoskeletal, CNS, and Other Diseases

  2016cites this paper
• Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

  2016cites this paper
• RANK and RANKL of Bones, T Cells, and the Mammary Glands

  2016cites this paper
• Advanced oxidation protein products induce apoptosis, and upregulate sclerostin and RANKL expression, in osteocytic MLO-Y4 cells via JNK/p38 MAPK activation

  2016cites this paper
• Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys.

  2016cites this paper
• Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis

  2016cites this paper
• Denosumab, cortical bone and bone erosions in rheumatoid arthritis

  2016cites this paper
• Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

  2015cites this paper
• Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells.

  2015cites this paper
• OPG‐Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice

  2015cites this paper
• Development of an in vivo rabbit ulnar loading model.

  2015cites this paper
• Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

  2015cites this paper
• Bone’s Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment

  2015cites this paper
• Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis

  2015influential citation
• Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys

  2015cites this paper
• Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

  2015cites this paper
• Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

  2015cites this paper
• DENOSUMAB-A NEW THERAPEUTIC OPTION FOR OSTEOPOROSIS

  2015cites this paper
• Skeletal Assessments in the Nonhuman Primate

  2015cites this paper
• Single-chain RANKL Provides Insights into RANK Receptor Oligomerization and a Novel Approach to Osteoclast Inhibition

  2015cites this paper
• Bone Quality Assessment Using High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)

  2015cites this paper
• True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo

  2015cites this paper
• Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals.

  2014cites this paper
• RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease

  2014cites this paper
• Inhibition of Cathepsin K Increases Modeling‐Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys

  2014cites this paper
• [Drug treatment of osteoporosis].

  2014cites this paper
• Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib

  2014cites this paper
• Medikamentöse Therapie der Osteoporose

  2014cites this paper
• A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF-α and RANKL.

  2014cites this paper
• Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice

  2014cites this paper
• Differing effects of denosumab and alendronate on cortical and trabecular bone.

  2014cites this paper
• Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension

  2014cites this paper
• A review of denosumab for the treatment of osteoporosis

  2014cites this paper
• Bone quality in prehistoric, Cis-Baikal forager femora: a micro-CT analysis of cortical canal microstructure.

  2014cites this paper
• Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

  2014cites this paper
• A review of denosumab for the treatment of osteoporosis

  2014cites this paper
• Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.

  2014cites this paper
• Intraosseous injection of rhBMP-2/calcium phosphate matrix improves bone structure and strength in the proximal aspect of the femur in chronic ovariectomized nonhuman primates.

  2013cites this paper
• RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.

  2013cites this paper
• Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

  2013cites this paper
• A case of an unusual subtrochanteric fracture in a patient receiving denosumab.

  2013cites this paper
• [RANKL inhibition in bone metastases].

  2013cites this paper
• The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies.

  2013cites this paper
• Chapter 83 – Denosumab for the Treatment of Osteoporosis

  2013cites this paper
• The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction

  2012cites this paper
• Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

  2012cites this paper
• Circulating Osteocalcin Level Is Not AssociatedWith Incident Type 2 Diabetes inMiddle-AgedMale Subjects Mean 8.4-year retrospective follow-up study

  2012cites this paper
• Active and passive anticytokine immune therapies: current status and development.

  2012cites this paper
• Pharmacological profiles and results of clinical studies of denosumab (RANMARK®), a human anti-RANKL antibody.

  2012cites this paper
• Circulating Osteocalcin Level Is Not Associated With Incident Type 2 Diabetes in Middle-Aged Male Subjects

  2012cites this paper
• Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

  2012cites this paper
• Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice.

  2012cites this paper
• Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

  2011cites this paper
• Risk of Newly Diagnosed Type 2 Diabetes Is Reduced in Users of Alendronate

  2011cites this paper
• Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.

  2011cites this paper
• Antiresorptive agents differ in their mode of action and morphological effects

  2011cites this paper